Paired Serum and Urine Concentrations of Biomarkers of Diethyl Phthalate, Methyl Paraben, and Triclosan in Rats

Susan L. Teitelbaum,1 Qian Li,1 Luca Lambertini,1 Fiorella Belpoggi,2 Fabiana Manservisi,2 Laura Falconi,2 Luciano Bua,2 Manori J. Silva,3 Xiaoyun Ye,3 Antonia M. Calafat,3 and Jia Chen1

1Department of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 2Cesare Maltoni Cancer Research Center, Ramazzini Institute, Bologna, Italy; 3National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Background: Exposure to environmental chemicals, including phthalates and phenols such as parabens and triclosan, is ubiquitous within the U.S. general population.

Objective: This proof-of-concept rodent study examined the relationship between oral doses of three widely used personal care product ingredients [diethyl phthalate (DEP), methyl paraben (MPB), and triclosan] and urine and serum concentrations of their respective biomarkers.

Methods: Using female Sprague-Dawley rats, we carried out two rounds of experiments with oral gavage doses selected in accordance with no observed adverse effect levels (NOAELs) derived from previous studies: 1,735 (DEP), 1,050 (MPB), 50 (triclosan) mg/kg/day. Administered doses ranged from 0.005 to 173 mg/kg/day, 10–100,000 times below the NOAEL for each chemical. Controls for the MPB and triclosan experiments were animals treated with olive oil (vehicle) only; controls for the DEP serum experiments were animals treated with the lowest doses of MPB and triclosan. Doses were administered for 5 days with five rats in each treatment group. Urine and blood serum, collected on the last day of exposure, were analyzed for biomarkers. Relationships between oral dose and biomarker concentrations were assessed using linear regression.

Results: Biomarkers were detected in all control urine samples at parts-per-billion levels, suggesting a low endemic environmental exposure to the three chemicals that could not be controlled even with all of the precautionary measures undertaken. Among the exposed animals, urinary concentrations of all three biomarkers were orders of magnitude higher than those in serum. A consistently positive linear relationship between oral dose and urinary concentration was observed (*R² > 0.80); this relationship was inconsistent in serum.

Conclusions: Our study highlights the importance of carefully considering the oral dose used in animal experiments and provides useful information in selecting doses for future studies.

Introduction

Exposure to environmental chemicals, including phthalates and phenols such as parabens and triclosan, is ubiquitous within the U.S. general population [Centers for Disease Control and Prevention (CDC) 2014]. There is growing interest in the possible adverse human health outcomes associated with exposure to these chemicals (Diamanti-Kandarakis et al. 2009).

Phthalates are used in a wide range of consumer goods (CDC 2014). Low molecular weight phthalates [e.g., diethyl phthalate (DEP)] are often found in personal care products (e.g., fragrances, shampoo, cosmetics). In rats, DEP is hydrolyzed to its monoester metabolite, monoethyl phthalate (MEP) (Albro and Moore 1974); DEP metabolism is assumed to be similar in humans (ATSDR 1995). Elimination half-lives of DEP and MEP in mammals have not been experimentally defined but are believed to be a few hours (Calafat and McKee 2006). Therefore, MEP has been used as a biomarker of recent exposure to DEP. Several health effects have been associated with elevated urinary concentrations of MEP, including adverse male reproductive outcomes (Duty et al. 2003; Hauser et al. 2007; Jönsson et al. 2005; Swan et al. 2005), altered neonatal behavioral and neurobehavioral development (Engel et al. 2009, 2010; Wolff et al. 2008), and increased breast cancer risk (López-Carrillo et al. 2010).

Parabens are commonly used as preservatives in personal care products, cosmetics, pharmaceuticals, and even in the processing of foods and beverages (Golden et al. 2005). Most Americans are exposed to various parabens, including methyl paraben (MPB) (CDC 2014). Because of their potential estrogenic activity, parabens have been suggested to play a role in breast cancer, albeit orders of magnitude lower than that of endogenous estrogens (Darbre and Harvey 2008; Golden et al. 2005); however, strong epidemiologic evidence is lacking ( McGrath 2003; Mirick et al. 2002). Parabens are hydroxylated to p-hydroxybenzoic acid, which can be conjugated and excreted in urine. p-Hydroxybenzoic acid and its conjugates are nonspecific metabolites of all parabens (Ye et al. 2006). However, the concentrations of total (free plus conjugated) urinary species of the parent parabens are considered valid biomarkers of paraben exposure in humans (Ye et al. 2006) and have been used as measures of environmental exposure to these chemicals in epidemiologic studies (Mervish et al. 2014; Wolff et al. 2010, 2014).

Triclosan is a commonly used antimicrobial in personal care and household products ranging from toothpaste, deodorant, and hand soap to cutting boards and textiles [U.S. Department of Health and Human Services (DHHS) 2015]. Public interest has been steadily increasing in the ubiquitous sources of exposure to this chemical. The hormonal activity of triclosan has not been clearly established owing to conflicting results from different investigations, including evidence of weak estrogenic (Chen et al. 2007; Svobodova et al. 2009) and androgenic activity (Chen et al. 2007), estrogen receptor antagonism (Ahn et al. 2008), and antiandrogenic properties (Chen et al. 2007). The excretion half-life of triclosan has been estimated as 11 hr for urine and 21 hr for plasma (Sandborg-Englund et al. 2006). When excreted in urine, triclosan is mainly in its conjugated form, whereas the percentage of free triclosan is higher in plasma (Sandborg-Englund et al. 2006). Urinary concentrations...
of triclosan (conjugated plus free species) can be used as a biomarker of exposure (Calafat et al. 2008).

Given the variability in the bioactivities of these chemicals, understanding the dose–response relationship is fundamental and essential for studying their potential biologic or health effects. Furthermore, the dose–response relationship may depart from linearity at low doses (Vandenberg et al. 2012), making dose extrapolation difficult and potentially unreliable. Thus, to evaluate risks or investigate the biological effects of environmental chemicals, it is critical to employ doses in animal experiments that are comparable to the human experience. However, the dose ranges used for DEP, MPB, and triclosan in animal studies have been wide and often orders of magnitude higher than humans are likely to encounter (Shiraishi et al. 2006; Stoker et al. 2010; Ve et al. 2010). On the basis of increasing evidence suggesting low-dose health effects of these chemicals, there is an urgent need for studies that utilize doses in the range of typical human exposure (Birnbaum 2012; Casals and Desvergne 2011).

The objective of this study was to investigate the relationship between oral doses of three widely used personal care product ingredients (DEP, MPB, and triclosan) in rats and the resulting urinary and serum biomarker concentrations. We used a traditional rat model, which is commonly employed in toxicology and risk assessment research. The rat has been used extensively for research in developmental and reproductive physiology and endocrinology and has been more thoroughly characterized in these research fields than other species, likewise for identifying likely human carcinogens (Gray et al. 2004; Maltoni et al. 1999). Although these experiments are part of a larger study examining personal care product ingredients and breast cancer risk, the results of our study will provide a foundation for future rodent-based health risk assessment studies for human exposure to these chemicals.

### Methods

**Materials and standards.** Diethyl phthalate (CAS 84–66–2, lot STBB0862V, 99% purity), methyl paraben (CAS 99–76–3, lot BCBG0852V, 99% purity), and triclosan (CAS 3380–34–5, lot 141254V, 97% purity) were supplied by Sigma Aldrich (Milan, Italy). Olive oil (lot 111275; Montalbano Agricola Alimentare Toscana, Florence, Italy) was used as vehicle to prepare all dosing solutions. During the experiment, each compound was stored in the dark at room temperature (20°C). The solutions to be used for the entire experiment (5 days) were prepared on the first day of treatment and were continuously stirred throughout the study; the stability of the solutions was confirmed by gas chromatography–mass spectrometry (GC/MS) (Neutron Laboratory, Modena, Italy).

**Experimental animals.** All animal study procedures were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC), following the principles of the Good Laboratory Practices and Standard Operating Procedure of the Ramazzini Institute (RI) facility. The protocol was also approved by the Mount Sinai IACUC. The animals were treated humanely and with regard for alleviation of suffering. This study was designed as a proof-of-concept experiment to determine oral doses to be used in a larger investigation focusing on the potential effects of these chemicals on mammary tissue gene expression; therefore, only female Sprague-Dawley (S-D) rats were used for this study. This strain belongs to the colony that has been used for over 40 years in the laboratory of the Cesare Maltoni Cancer Research Centre of the RI facility. The animals were randomly distributed into 10 groups in order to minimize the number of animals from each litter in the same group. Rats were identified by ear punch in accordance with the Jackson Laboratory system. Throughout the treatment period before urine and blood collection, animals were housed in standard polycarbonate cages (41 cm × 25 cm × 15 cm) with stainless steel wire tops and a shallow layer of white wood shavings for bedding; two or three rats were housed per cage. Cages were identified by cards indicating the experiment, the group, and the experimental number/pedigree number of each animal. During each experiment, all animals were kept in a single room at 23°C ± 3°C and 40–60% relative humidity. Lighting was natural or artificial to maintain a 12 hr light/dark cycle. Before treatment was started, animals were weighed and dosed based on the average weight of the experimental group (milligrams per kilogram body weight). Rat feed (Laboratorio Dr Piccioni, Milan, Italy) and tap water were provided ad libitum. Each lot of feed and tap water was periodically analyzed for biologicals (bacteria) and chemicals (mycotoxins, pesticides, arsenic, lead, mercury, selenium) but not for DEP, triclosan, or MPB. The experimental design is shown in Table 1. To reduce the possibility of DEP, triclosan, or MPB contamination, all cages, containers, and syringes used during the experiments were washed without detergent; instead, these items were cleaned by exposure to hot water for an extended period of time.

**Chemical treatment.** Two rounds of experiments (Table 1) were performed to identify the oral gavage–administered dose of each chemical that resulted in urinary concentrations of the corresponding biomarker within the ranges reported in the U.S. National Health and Nutrition Examination Survey (NHANES) (CDC 2014). For each round, three doses were selected for each chemical according to no observed adverse effect levels (NOAELs) that were defined based on previous studies as 1,735 mg/kg/day for DEP (Brown et al. 1978; Moody and Reddy 1978; Oishi and Hiraoka 1980), 1,050 mg/kg/day for MPB (U.S. EPA 2005), and 50 mg/kg/day for triclosan.

### Table 1. Administered doses and available biological samples.*

| Compounds            | Administered dose<sup>a</sup> | Rats<sup>b</sup> | Samples<sup>b</sup> |
|----------------------|-------------------------------|-----------------|---------------------|
| **Experiment 1**     |                               |                 |                     |
| Diethyl phthalate    | NOAEL/10                      | 173.5           | 5                   | Yes | No |
|                      | NOAEL/100                     | 17.35           | 5                   | Yes | No |
|                      | NOAEL/200                     | 6.88            | 5                   | Yes | No |
| Methyl paraben       | NOAEL/10                      | 106             | 5                   | Yes | No |
|                      | NOAEL/100                     | 10.5            | 5                   | Yes | No |
|                      | NOAEL/200                     | 5.25            | 5                   | Yes | No |
| Triclosan            | NOAEL/10                      | 5               | 5                   | Yes | No |
|                      | NOAEL/100                     | 0.5             | 5                   | Yes | No |
|                      | NOAEL/200                     | 0.25            | 5                   | Yes | No |
| Control              | Olive oil                     | —               | 5                   | Yes | No |
| **Experiment 2**     |                               |                 |                     |
| Diethyl phthalate    | NOAEL/200                     | 8.675           | 5                   | Yes | Yes |
|                      | NOAEL/10,000                  | 0.1735          | 5                   | Yes | Yes |
|                      | NOAEL/100,000                 | 0.01735         | 5                   | Yes | Yes |
| Methyl paraben       | NOAEL/200                     | 5.25            | 5                   | Yes | Yes |
|                      | NOAEL/10,000                  | 0.105           | 5                   | Yes | Yes |
|                      | NOAEL/100,000                 | 0.0105          | 5                   | Yes | Yes |
| Triclosan            | NOAEL/200                     | 0.25            | 5                   | Yes | Yes |
|                      | NOAEL/1,000                   | 0.05            | 5                   | Yes | Yes |
|                      | NOAEL/10,000                  | 0.005           | 5                   | Yes | Yes |
| Control              | Olive oil                     | —               | 5                   | Yes | Yes |

NOAEL, no observed adverse effect level.<sup>a</sup> NOAEL (mg/kg/day) for diethyl phthalate = 1,735; methyl paraben = 1,050; triclosan = 50. <sup>b</sup>Only pooled urine samples available in experiment 1; individual urine and serum samples available in experiment 2.
Female S-D rats were treated by oral gavage daily for 5 days. Each treatment group consisted of 5 rats, including a control group with rats treated with olive oil only. A total of 50 rats in 10 experimental groups (three chemicals × three doses + one control) were involved in each experimental round. For both experimental rounds, the dosing day was designated as day 0, and urine and serum samples were collected on day 6. The first experiment was carried out with rats at 16 weeks of age; the selected testing doses were NOAEL/10, NOAEL/100, and NOAEL/200 for each of the three target chemicals. The second experiment was carried out with rats at 27 weeks of age, and the testing doses were NOAEL/200, NOAEL/10,000, and NOAEL/100,000 for DEP and MPB, and NOAEL/200, NOAEL/1,000, and NOAEL/10,000 for triclosan.

To minimize external contamination, the olive oil and chemicals were stored in glass containers and administered using 5-mL glass syringes. DEP, triclosan, and MPB were not detected in the olive oil used as vehicle using GC/MS at Neutron Laboratory, Modena, Italy (http://www.neoton.it). Biological samples were collected in polypropylene vials. At the end of the experiment and after the urine collection (day 6), each rat was sacrificed by CO2 inhalation.

**Urine collection.** The morning after completing treatment (day 5), rats were moved from their experimental cages to metabolic cages (TECNIPLAST S.p.A., Italy), where each rat was individually housed for 24 hr without food but with water ad libitum. Metabolic cages are specifically designed to prevent fecal contamination of urine. Twenty-four-hour urine was collected and placed in pre-labeled polypropylene vials. Furthermore, a single dose-group urine pool composed of 200 μL of urine from each animal in the group was created and stored in a separate vial. Urine vials were placed in cryoboxes and frozen at –20°C, then shipped on dry ice to the CDC's NCEH laboratory. Upon arrival, the samples were stored at –70°C until analysis.

**Serum collection.** Serum samples were collected only for the second experiment. After sacrifice, whole blood (5 mL) was collected from the inferior vena cava using a 5-mL glass syringe, placed in a tube without anticoagulating agents, and left at room temperature for 30 min. The clot was removed by centrifugation at 2,500 × g for 10 min. The serum (supernatant) was transferred into a clean polypropylene vial using a glass Pasteur pipette. The serum samples were placed in a cryobox and then stored at –20°C, cycled on dry ice to the CDC’s NCEH laboratory. Upon arrival, the samples were stored at –70°C until analysis.

**Laboratory analysis.** Urine and serum samples were analyzed at the CDC’s NCEH laboratories for MEP, the common biomarker of DEP, triclosan, and MPB. MEP, the specific monoester metabolite of DEP, is measured as a biomarker of exposure to DEP because measurement of the parent compound poses a number of challenges (Koch and Calafat 2009). Phthalate diesters are ubiquitous in the environment, can be detected in the laboratory setting, and are quickly metabolized into their hydrolytic monoester (Koch and Calafat 2009). Therefore, MEP is the preferred biomarker because it is not as prone to contamination (Koch and Calafat 2009). Analytical methods for these three biomarkers (MEP, MPB, and triclosan) have been published (Silva et al. 2007a; Ye et al. 2005, 2008). Conjugated species of the biomarkers were enzymatically hydrolyzed, pre-concentrated by on-line solid phase extraction, and separated from other matrix components by high performance liquid chromatography. Quantitation was achieved by isoipe dilution tandem mass spectrometry. Limits of detection (LOD), calculated as three times the standard deviation as the concentration approaches zero (Taylor 1987), for MEP, MPB, and triclosan were 0.6, 1.0, 2.3 ng/mL in urine, and 0.6, 0.1, 1.1 ng/mL in serum, respectively. Standards, quality control samples, and reagent blanks were included in each analytical batch along with the experimental samples. Quality control samples were evaluated in accordance with standard statistical probability rules (Caudill et al. 2008).

**Statistical methods.** For the second experiment, where individual urine and serum samples were available, we examined the associations between oral dose and individual urinary/serum biomarker concentration using linear regression models. Values below the LOD were imputed as LOD divided by the square root of two. We also examined the relationship between urinary and serum biomarker concentrations using Spearman correlation coefficients. Serum MEP concentrations in samples from controls treated with olive oil (mean, 136.2 ± 37.8 ng/mL) were greater than serum concentrations measured in samples from animals with the lowest DEP dose (mean, 15.8 ± 8.9 ng/mL), indicating a potential contamination problem. Investigation of both the animal experiment protocol and the analytic laboratory protocol did not reveal any obvious reasons for these results. To avoid sacrificing additional animals, a decision was made to use the MEP concentration in serum from the 10 rats in the lowest dose categories of the triclosan and MPB groups as the control concentrations in the regression analyses for the association between oral DEP and serum MEP. Statistical analyses were performed using SAS 9.3 for Windows (SAS Institute Inc., Cary, NC, USA).

Biomarker concentrations measured in the rats’ urine were compared with the 2009–2010 National Health and Nutrition Examination Survey urine concentration median and 95th percentile (ng/mL) for females. These concentrations were 59.6 and 988, respectively, for MEP; 106 and 1,230, respectively, for MPB; and 10.5 and 488, respectively, for triclosan (CDC 2014).

**Results**

**Associations between urinary metabolite concentration and oral dose.** In the first experiment, only a single pooled urine sample from each experimental group (five rats) was analyzed for MEP, MPB, or triclosan. The results are presented in Table 2. The underlying goal of these experiments was to find oral doses of the three chemicals that resulted in urinary biomarker concentrations in the range reported for the U.S. female population. All dose groups in the first experiment had concentrations that greatly exceeded the 95th percentile (100 times) and the geometric mean (1,000 times) as reported in NHANES (CDC 2014). Therefore, we conducted a second experiment using much lower doses: NOAEL/200, NOAEL/10,000, and NOAEL/100,000 for DEP and MPB, and NOAEL/200, NOAEL/1,000, and NOAEL/10,000 for triclosan. In contrast to the first set of experiments, individual urine samples from the five rats in each treatment group were analyzed. Figure 1 presents the mean (± standard deviation) for urinary concentrations of MEP, MPB, and triclosan for each dose group. For all three chemicals, the mean urinary concentrations for the lower oral doses were in the range of urinary concentrations reported for the U.S. female general population (CDC 2014). As shown in Table 3, the urinary concentrations demonstrated a strong linear relationship with the oral doses for each of the three chemicals. Moreover, all $R^2$ values were greater than 0.80 ($p < 0.001$).

**Associations between metabolite serum concentration and oral dose.** In the second experiment, we examined the relationship between serum concentration and oral dose of the three chemicals. Although MEP was detected in all serum samples, MPB was detected in 60% of the serum samples (Table 2). Triclosan was detected in the serum of all dosed animals, whereas all control animals had undetectable serum triclosan concentrations. In general, the concentrations...
of MEP, MPB, and triclosan in urine were considerably higher than those in serum: ~10³ times higher for MEP, ~10⁴ times higher for MPB, and ~10 times higher for triclosan. Spearman correlation coefficients between urine and serum concentrations were 0.44 (MEP), 0.23 (MPB), and 0.98 (triclosan). As shown in Table 3, a relationship between oral dose and biological concentration of MEP was present in urine only ($R^2 = 0.84$ in urine and 0.04 in serum). For MPB, this relationship existed in both urine and serum but was stronger in urine ($R^2 = 0.85$ in urine and 0.57 in serum). The decreased strength of the relationship in serum may be because of the higher detection frequency in the controls than in the two lower oral doses. For triclosan, the relationship was equally strong in both fluids ($R^2 = 0.88$ in urine and 0.88 in serum).

**Discussion**

We carried out a systematic dosing study in a rodent model and identified oral doses of three commonly used personal care product ingredients that resulted in comparable urinary biomarker concentrations to those observed in the U.S. female population. The results of this study may provide important information for future risk assessments of these chemicals that can be reliably translated to human populations.

The true daily intake of DEP, MPB, and triclosan by humans is unknown; however, several efforts have been made to estimate intake, and the oral doses used in experiment 2 compare well. For example, the NOAEL/100,000 experimental oral dose for both DEP and MPB (17.4 and 10.5 μg/kg/day, respectively) were only one order of magnitude higher than the estimated median (95th percentile in micrograms per kilogram per day) daily intake estimates of 1.7 (25) for DEP in the general Canadian female population ages 29–39 (Saravananbavan et al. 2014) and 0.13 (0.36) for MPB in the general Chinese adult female population (Liao et al. 2013). The lowest oral dose of triclosan (NOAEL/10,000 = 0.5 μg/kg/day) was within the range of the estimated median (90th percentile in micrograms per kilogram per day) daily intake among an adult Belgian study population [0.017 (0.565)] (Geens et al. 2015). Estimation of daily intake depends on knowledge of the toxicokinetics, including administration, distribution, metabolism, and excretion (Soeborg et al. 2014); not all of this information was necessarily available to the cited authors for performing these calculations. However, the doses used in the second round of experiments do fall within the range of estimates calculated from adult human populations and provide support for the use of these oral doses in future translational animal experiments.

When conducting exposure studies with low doses, contamination can be a concern, especially when the chemicals being studied are ubiquitous in the environment. Careful protocols were implemented in the animal laboratory to minimize all potential sources of contamination as much as possible. These precautions included ensuring that the wearing of perfume and other scented products was avoided by staff, testing the olive oil (vehicle) for the presence of the three chemicals, using glass storage containers and glass syringes for all chemicals and solutions, and employing cleaning procedures that used only hot water without detergent. Fecal contamination of the urine could have occurred, although this source of contamination was highly unlikely owing to the design of the metabolic cages used to collect the urine samples. Similar strict protocols were also implemented in the analytic laboratory to avoid external contamination with the target biomarkers (Ye et al. 2013).

The detection of trace concentrations (i.e., parts per billion) of the biomarkers in all of the control urine samples suggests low endemic environmental exposure of the three chemicals that could not be controlled even with the precautionary measures undertaken. However, the magnitude of the possible contamination was far below the measured concentrations in the majority of urine samples from rats that received the experimental doses. The measured urine and serum concentrations likely resulted from a combination of the administered dose and the low endemic environmental dose. Future studies to repeat or extend the approaches presented herein would benefit from the use of stable-isotope-labeled chemicals in the dosing solution so that the biomarker measurements could be confidently attributed to the administered chemical exposure. To further investigate the unexpected detection of MEP in the serum from the 5 control rats (see Supplemental Material, Table S1, for individual animal results), samples from animals in the lowest

---

**Table 2. Urinary and serum biomarker concentrations by administered oral doses of diethyl phthalate, methyl paraben, and triclosan.**

| Biomarker       | Oral dose NOAEL/X | Urine concentration (ng/mL), pooled sample | Oral dose NOAEL/X | Urine concentration (ng/mL), pooled sample | Serum n > LOD/total samples | Serum concentration (ng/mL), Mean ± SD |
|-----------------|-------------------|------------------------------------------|-------------------|------------------------------------------|-----------------------------|----------------------------------------|
| Monoethyl phthalate (MEP) | 5 | Monoethyl phthalate (MEP) | | | | |
| 10 | 172.5 | 2.02 × 10³ | 200 | 8.88 | 1.64 × 10³ ± 6.97 × 10² | 5/5 | 19.12 ± 7.56 |
| 100 | 17.35 | 2.43 × 10³ | 10,000 | 0.174 | 5.53 × 10³ ± 2.87 × 10² | 5/5 | 21.66 ± 9.21 |
| 200 | 8.68 | 2.28 × 10³ | 100,000 | 0.0174 | 2.87 × 10³ ± 5.31 × 10² | 5/5 | 15.76 ± 8.89 |
| 0² | | 3.22 × 10³ | | | | |
| Methyl paraben (MPB) | 5 | Methyl paraben (MPB) | | | | |
| 10 | 105 | 5.00 × 10³ | 200 | 5.25 | 4.32 × 10³ ± 1.74 × 10³ | 5/5 | 1.64 ± 0.48 |
| 100 | 10.5 | 9.02 × 10³ | 10,000 | 0.105 | 1.39 × 10³ ± 7.09 × 10² | 1/5 | 0.4 | |
| 200 | 5.25 | 7.70 × 10³ | 100,000 | 0.0105 | 1.44 × 10³ ± 9.72 × 10² | 1/5 | 0.4 | |
| 0² | | 3.85 × 10³ | | | | |
| Triclosan (TCS) | 5 | Triclosan (TCS) | | | | |
| 10 | 5 | 7.91 × 10³ | 200 | 0.25 | 1.70 × 10³ ± 5.19 × 10² | 5/5 | 186 ± 40.69 |
| 100 | 0.5 | 1.28 × 10³ | 1,000 | 0.006 | 2.88 × 10³ ± 9.02 × 10² | 5/5 | 46.88 ± 20.76 |
| 200 | 0.25 | 5.94 × 10³ | 10,000 | 0.0005 | 5.22 × 10³ ± 1.86 × 10³ | 5/5 | 4.72 ± 2.20 |
| 0² | | 5.4 × 10³ | | | | |

Abbreviations: LOD, Limit of detection; NOAEL, no observed adverse effect level.

²Biomarker concentration measured in a single sample from a urine pool from five individual rats for each dose group. ³Mean of biomarker concentrations measured in five individual urine samples for each dose group. All biomarkers measured in urine samples were detectable (> LOD); LOD (ng/mL) in urine for MEP, MPB, and TCS were 0.6, 1.0, and 2.3, respectively. For comparison, the 2009–2010 National Health and Nutrition Examination Survey urine concentration median and 95th percentile (ng/mL) for females were 59.6 and 988, respectively, for MEP; 106 and 1,280, respectively, for MPB, and 10.5 and 488, respectively, for triclosan (CDC 2014). ⁴Monoethyl phthalate was used as the biomarker of exposure to diethyl phthalate. One control group of 5 rats was used for experiment 1; the pooled urine sample was analyzed for all three biomarkers (MEP, MPB, and triclosan). One control group of 5 rats was used for experiment 2; the 5 individual urine samples were analyzed for all three biomarkers (MEP, MPB, and triclosan). MEP serum controls: MEP concentrations measured in serum from 5 MPB and 5 TCS animals treated with the lowest oral dose (MPB: NOAEL/100,000: TCS: NOAEL/10,000); see "Methods" for details. Concentration measured in the single serum sample among dose group with measurement > LOD; LOD (ng/mL) in serum for MEP, MPB, and triclosan were 0.6, 0.1, and 1.1, respectively.
Paired serum and urine biomarkers in rats

Dose groups of the other two chemicals (MPB and triclosan) were analyzed for MEP. The assumption was that these rats would be suitable controls if no MEP contamination had occurred. Trace MEP concentrations were similar among these 10 rats and were slightly lower than the serum concentrations of the group of rats exposed to the lowest DEP dose.

This study was designed to be a dose-calibration investigation. This type of study is typically smaller than a main experiment and therefore can provide only limited information about the sources and magnitude of variation of responses. The sample size was in line with the number of animals per dose group suggested by the Organisation for Economic Co-operation and Development (OECD) guidelines (OECD 2010) for toxicokinetik studies. The variability observed among the identically dosed rats is expected owing to inter-individual differences in absorption, distribution, metabolism, and excretion of the target analytes, in addition to differences in the water intake of the animals during the experiment; the same variability would be expected in humans. Although the same oral dose (NOAEL/200) was administered in experiments 1 and 2, the differences in urinary concentrations between the two experiments likely reflect the normal variability within the animals, that the experiments were performed at different times, and that the animals were of different ages at the start of each experiment. Thus, the two experiments should be considered individually. Variability in the concentrations of these metabolites among dosed animals has been observed in S-D rats dosed with dibutyl phthalate and di(2-ethylhexyl) phthalate (Calafat et al. 2006; Silva et al. 2007b), other phthalates (Silva et al. 2011), and other non-persistent chemicals, specifically phthalate alternatives (Silva et al. 2012).

Gavage is preferred over other routes of exposure to environmental chemicals when very low doses are used (Vandenbergh et al. 2014). It is difficult to ascertain the true intake when chemicals are mixed into food or drinking water ad libitum. Although gavage does not perfectly represent a model of human dietary exposure, this route has been employed in numerous studies assessing potential carcinogenic hazards (Perera et al. 1989).

Animal models are useful tools for risk assessment of toxic chemicals and for identification of their potential physiologic consequences. Given the uncertainty of dose extrapolation, it is ideal to perform risk assessment using exposure conditions that mimic human experience. We chose the S-D rat as our model system because it has been shown to be one of the most physiologically relevant and genetically defined animal models for studying human sporadic breast cancer (Maltoni et al. 1996, 1997). The S-D rat model from the RI colony could be considered a human-equivalent model, particularly for breast lesions (non-neoplastic, pre-neoplastic, and neoplastic), that will allow us to translate rodent data to humans in future research (Teitelbaum et al. 2015). Furthermore, endocrine effects, which may occur even at the lowest doses, are difficult to detect without a highly sensitive experimental model. S-D rats are extremely sensitive and are recommended by the Endocrine Disruptor Screening Program of the U.S. Environmental Protection Agency (EPA), which considers these animals particularly appropriate and relevant for identifying, extrapolating, and predicting likely effects in humans (U.S. EPA 2009). In a review of the literature, we found that the range of oral doses for DEP, MPB, and triclosan used in animal experiments was wide and, in almost all cases, much greater than the doses used in our exposure study (see Supplemental Material, Table S2, for a list of these studies). For example, in an investigation of estrogen-dependent responses to triclosan exposure in rats, triclosan was administered by oral gavage from postnatal day (PND) 19 to 21, and the oral dose ranged from 1.18 to 300 mg/kg/day (Stoker et al. 2010). In a study investigating MPB exposure and estrogenic effects, MPB was administered by oral gavage from PND 21 to 40 in oral doses ranging from 62.5 to 1,000 mg/kg/day (Vo et al. 2010). In another investigation of DEP exposure and endocrine-mediated properties, the chemical was administered by oral gavage for 28 days in doses ranging from 40 to 1,000 mg/kg/day (Shiraishi et al. 2006). In most cases, the lowest doses far exceeded the highest doses (0.25 mg/kg/day for triclosan, 5.25 mg/kg/day for MPB, 8.675 mg/kg/day for DEP) used in the present study. Importantly, only the lowest doses in our study, which were 500–5,000 times lower than the highest dose, resulted in biological levels that were comparable to those reported by NHANES. Therefore, most published studies employ doses that are not likely to be representative of exposures experienced by the U.S. population and are likely to be orders of magnitude higher.

The NOAEL, which can be determined either by experiment or through observation, denotes the highest level of exposure at which there is no biologically or statistically significant increase in the frequency or severity of any adverse effects in an organism when compared with a control (IPCS 1990). In the

![Figure 1. Urinary metabolite concentrations of monoethyl phthalate, methyl paraben, and triclosan by oral dose (n = 5 rats per dose group) and in NHANES (2009–2010). Abbreviations: DEP, diethyl phthalate; MPB, methyl paraben; NHANES, National Health and Nutrition Examination Survey; NOAEL, no observed adverse effects level; TCS, triclosan. For oral doses of DEP, monoethyl phthalate (MEP) is measured as the biomarker and presented as the urinary metabolite concentration. Data represent the 50th, 75th, and 90th percentiles of urine concentrations (in ng/mL) for the U.S. female population (> 6 years old) from NHANES (2009–2010). All other data represent the mean ± SD for urine concentrations in experimental animals.](image-url)

| Exposure (oral dose) | Outcome (metabolite) | Urine | Serum |
|---------------------|----------------------|-------|-------|
| DEP                 | MEP                  | 0.84  | 0.04  |
| MPB                 | MPB                  | 0.85  | 0.57  |
| TCS                 | TCS                  | 0.88  | 0.98  |

Abbreviations: DEP, diethyl phthalate; MEP, monoethyl phthalate; MPB, methyl paraben; TCS, triclosan.
present study, it was necessary to administer oral doses that were many orders of magnitude lower than the NOAEL to observe urinary metabolite concentrations that were within the ranges reported for the U.S. population in NHANES 2009–2010 (CDC 2014). As noted above, the potential low endemnic environmental exposure must be considered when evaluating the oral administered dose, highlighting the importance of identifying doses that are a realistic representation of human exposure to these chemicals to aid in the design of future animal experiments.

The results of this study indicate that oral exposure to three commonly used environmental chemicals, that is, DEP, MPB, and triclosan, has a strong linear relationship with the urinary concentrations of their corresponding biomarkers, but this relationship is not as uniformly strong in serum. The relatively weak association between-administered oral gavage dose of DEP and MPB and the serum concentrations of their biomarkers exemplifies why there is growing concern about the use of the proper biologic matrix for exposure assessment (Calafat et al. 2013). The timing of urine and serum collection was the same, that is, 24 hr after completing treatment; however, urine was collected over a 24-hr period, and blood was collected as a spot sample. The half-lives of the investigated chemicals are relatively short, such that the interval between exposure and biomarker measurement may influence the findings if half-lives differ according to biologic matrix. Moreover, in general, the concentrations of MEP, MPB, and triclosan were much lower in serum than in urine, which is in accord with results obtained in human studies (Frederiksen et al. 2010). Taken together, the positive linear association of oral dose with urinary biomarkers, the higher percentages of urinary biomarkers detected compared with serum biomarkers, and the relatively low concentration of biomarkers in serum all support the use of urine as the appropriate biologic matrix for assessing exposure to these non-persistent chemicals.

Conclusion

In this study, we identified a range of oral doses of three common environmental chemicals that result in urinary biomarker concentrations in a rat model that are consistent with the biomarker concentrations measured in the rodents’ urine, the results of this study highlight the importance of carefully considering the oral dose used in animal experiments and provide useful information for selecting doses of DEP, MPB, and triclosan in future studies that evaluate their biological effects in experimental settings.

Editor’s Note: Information that was provided in the Advance Publication regarding NOAEL values defined for DEP and triclosan has been revised to indicate the individual studies on which the NOAEL were based, including Brown et al. (1978), Moody and Reddy (1978), and Oishi and Hiraga (1980) for DEP, and Goldsmith and Craig (1983) and Rodriguez and Sanchez (2010) for triclosan.

REFERENCES

Ahn KC, Zhao B, Chen J, Chereedinchko G, Samnari E, Denison MS, et al. 2008. In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens. Environ Health Perspect 116:1203–1210; doi:10.1289/ehp.11200.

Albro PW, Moore B. 1974. Identification of the metabolites of simple phthalate diesters in rat urine. J Chromatogr 94:209–218.

ATSDR (Agency for Toxic Substances and Disease Registry). 1995. Toxicological Profile for Diethyl Phthalate. Atlanta, GA:U.S. Department of Health and Human Services, Public Health Services. Available: http://www.atsdr.cdc.gov/toxprofiles/tp67.pdf [accessed 25 February 2015].

Birnbaum LS. 2012. Environmental chemicals: evaluating low-dose effects [Editorial]. Environ Health Perspect 120:A143–A144; doi:10.1289/ehp.1205179.

Brown D, Butterworth KR, Gaunt IF, Grasso P, Gangoli SD. 1978. Short-term oral toxicity study of diethyl phthalate in the rat. Food Cosmet Toxicol 16:415-422.

Calafat AM, Brock JW, Silva MJ, Gray LE Jr, Reidy JA, Barr DB, et al. 2006. Urinary and amniotic fluid levels of phthalate monooesters in rats after the oral administration of di(2-ethylhexyl) phthalate and di-n-butyl phthalate. Toxicology 217:22–30.

Calafat AM, Koch HM, Swan SH, Hauser R, Goldman LR, Lanphear BP, et al. 2013. Misuse of blood serum to assess exposure to bisphenol A and phthalates [Letter]. Breast Cancer Res 15:403; doi:10.1186/bcr3494.

Calafat AM, McKee RH. 2006. Integrating biomonitoring exposure data with the risk assessment process: phthalates [diethyl phthalate and di(2-ethylhexyl) phthalate] as a case study. Environ Health Perspect 114:1783–1789; doi:10.1289/ehp.060683.- Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. 2008. Urinary concentrations of triclosan in the U.S. population: 2003–2004. Environ Health Perspect 116:303–307; doi:10.1289/ehp.10768.

Casals-Casas C, Desvergne B. 2011. Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol 73:135–162.

Caudill SP, Schleicher RL, Pirkle JL. 2008. Multi-rule quality control for the Age-Related Eye Disease Study. Stat Med 27:4094–4106.

CDC (Centers for Disease Control and Prevention). 1995. Toxicological Profile for Diethyl Phthalate. Atlanta, GA:U.S. Department of Health and Human Services, Public Health Services. Available: http://www.atsdr.cdc.gov/toxprofiles/tp67.pdf [accessed 25 February 2015].

Chen J, Ahn KC, Gee NA, Gee SJ, Hammock BD, Lasley BL. 2007. Antiandrogenic properties of parabens and other phenolic containing small molecules in personal care products. Toxicol Appl Pharmacol 221:278–294.

Dobrée PD, Harvey PW. 2008. Paraben esters: review of recent studies of endocrine toxicity, absorption, estrogenic and human exposure, and discussion of potential human health risks. J Appl Toxicol 28:561–578.

DHHS (U.S. Department of Health and Human Services). 2015. Household Products Database. Health & Safety Information on Household Products. Available: http://householdproducts.nlm.nih.gov/ [accessed 25 February 2015].

Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. 2009. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 30:293–342.

Duty SM, Singh NP, Silva MJ, Barr DB, Brock JW, Ryan L, et al. 2003. The relationship between environmental exposures to phthalates and DNA damage in human sperm using the neutral comet assay. Environ Health Perspect 111:1164–1169; doi:10.1289/ehp.7576.

Engel SM, Miodovnik A, Canfield RL, Zhu C, Silva MJ, Calafat AM, et al. 2010. Prenatal phthalate exposure is associated with childhood behavior and executive functioning. Environ Health Perspect 119:565–571; doi:10.1289/ehp.0901470.

Engel SM, Zhu C, Berkowitz GS, Calafat AM, Silva MJ, Miodovnik A, et al. 2009. Prenatal phthalate exposure and performance on the Neonatal Behavioral Assessment Scale in a multietnic sample of California newborns. Environ Health 8:522–528.

Frederiksen H, Jørgensen N, Andersson AM. 2010. Correlations between phthalate metabolites in urine, serum, and seminal plasma from young Danish men determined by isotope dilution liquid chromatography tandem mass spectrometry. J Anal Toxicol 34:400–410.

Gees T, Diru AC, Dirincic E, Malvaranjan G, Van Gaal L, Jores P, et al. 2015. Daily intake of bisphenol A and triclosan and their association with anthropometric data, thyroid hormones and weight loss in overweight and obese individuals. Environ Int 76:98–105.

Golden R, Gandy J, Vollmer G. 2005. A review of the endocrine activity of parabens and implications for potential risks to human health. Crit Rev Toxicol 35:435–458.

Goldsmith LA, Craig DK. 1983. 90-day Oral Toxicity Study in Rats with FAT 80/023. /Final Report. LBI Project No. 21188. Kensington, MD:Linton Bioinetics, Inc.

Gross LE Jr, Willin V, Noriega N, Lambrecht C, Furr J, Stoker TE, et al. 2004. Use of the laboratory rat as a model in endocrine disruptor screening and testing. ILAR J 45:425–437.

Hauser R, Meeker JD, Singh NP, Silva MJ, Ryan L, Duty S, et al. 2007. DNA damage in human sperm is related to urinary levels of phthalate monooester and oxidative metabolites. Hum Reprod 22:685–695.

ICPS (International Programme on Chemical Safety). 1990. Principles for the Toxicological Assessment of Pesticide Residues in Food. Environmental Health Criteria 104. Geneva:World Health Organization. Available: http://www.inchem.org/documents/ehc/ehc104.htm.

Jönsson BA, Richhoff J, Rylander L, Siwercman A, Hagmar L. 2005. Urinary phthalate metabolites and biomarkers of reproductive function in young men. Epidemiology 16:487–493.

Koch HM, Calafat AM. 2009. Human body burdens of chemicals used in plastic manufacture. Philos Trans R Soc Lond B Biol Sci 364:2063–2078.

Liao C, Liu F, Kannan K. 2013. Occurrence of and diagnostic potential of urinary Di(2-ethylhexyl) phthalate metabolite concentrations in a rat model that are consistent with the biomarker concentrations measured in the rodents’ urine, the results of this study highlight the importance of carefully considering the oral dose used in animal experiments and provide useful information for selecting doses of DEP, MPB, and triclosan in future studies that evaluate their biological effects in experimental settings.
cancer risk in northern Mexico. Environ Health Perspect 118:539–544; doi:10.1289/ehp.0801091.

Maltoni C, Minardi F, Belpoggi F, Pinto C, Lenzi A, Filippini E. 1996. Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. In: The Scientific Bases of Cancer Chemoprevention (Maltoni C, Soffritti M, Davis W, eds). New York:Elsevier Science Publishers, 197–217.

Maltoni C, Minardi F, Pinto C, Belpoggi F, Bua L. 1997. Results of three life-span experimental carcinogenicity and anticarcinogenicity studies on tamoxifen in rats. Ann NY Acad Sci 895:10–26.

McGrath KG. 2003. An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving. Eur J Cancer Prev 12:479–485.

Mervish N, McGovern KJ, Teitelbaum SL, Pinney SM, Windham GC, Biro FM, et al. 2014. Dietary predictors of urinary environmental biomarkers in young girls, BCERP, 2004–2007. Environ Res 133:12–19.

Mircik DK, Davis S, Thomas DB. 2002. Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst 94:1578–1580.

Moody DE, Reddy JK. 1978. Hepatic peroxisome (microbody) proliferation in rats fed plasticizers and related compounds. Toxicol Appl Pharmacol 45:497–504.

OECD (Organisation for Economic Co-operation and Development). 2010. Test No. 417: Toxicokinetics, OECD Guidelines for the Testing of Chemicals, Section 4. Paris:OECD. Available: http://www.oecd-ilibrary.org/docserver/download/97841701x.pdf?expires=1442594277&id=id&accname=guest&checksum=3C49FE8D998526FD68D39EBAD418852. [accessed 25 February 2015].

Oishi S, Hiraga K. 1980. Testicular atrophy induced following oral ingestion in humans. J Toxicol Environ Health A 8:1861–1873.

Saravanabhavan G, Walker M, Guay M, Aylward L. 2014. Urinary excretion and daily intake rates of diethyl phthalate in the general Canadian population. Sci Total Environ 500–501:191–198.

Shiraishi K, Miyata K, Houshyam S, Imanaka N, Umano T, Minobe Y, et al. 2006. Subacute oral toxicity study of diethylphthalate based on the draft protocol for “Enhanced OECD Test Guideline no. 407.” Arch Toxicol 80:10–18.

Silva MJ, Furr J, Preau JL Jr, Samandar E, Gray LE, Calafat AM. 2012. Identification of potential biomarkers of exposure to di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH), an alternative for phthalate plasticizers. J Expo Sci Environ Epidemiol 22:204–211.

Silva MJ, Furr J, Samandar E, Preau JL Jr, Gray LE, Needham LL, et al. 2011. Urinary and serum metabolites of di-n-pentyl phthalate in rats. Chemosphere 82:431–436.

Silva MJ, Samandar E, Preau JL Jr, Reidy JA, Needham LL, Calafat AM. 2007a. Quantification of 22 phthalate metabolites in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 890:106–112.

Silva MJ, Samandar E, Reidy JA, Hauser R, Needham LL, Calafat AM. 2007b. Metabolite profiles of di-n-butyl phthalate in humans and rats. Environ Sci Technol 41:7578–7580.

Søeborg T, Frederiksen H, Andersson AM. 2014. Effects of bisphenol A and other ubiquitous organic environmental chemicals on the female Wistar rat. Toxicol Sci 117:45–53.

Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Needham LL, et al. 2005. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect 113:1056–1061; doi:10.1289/ehp.8100.

Taylor JK. 1987. Quality Assurance of Chemical Measurements. Chelsea, MI:Lewis Publishers.

Teitelbaum SL, Belpoggi F, Reinlib L. 2015. Advancing research on endocrine disrupting chemicals in breast cancer: expert panel recommendations. Reprod Toxicol 54:141–147; doi:10.1016/j.reprotox.2014.12.015.

U.S. EPA. 2005. Inert Reassessment of Methyl p-Hydroxybenzoate. Action Memorandum from Pauline Wagner, Chief Inert Ingredient Assessment Branch, Registration Division (7505P) to Lois A. Rossi, Director, Registration Division (7505P).

Washington, DC:U.S. Environmental Protection Agency, Offices of Prevention, Pesticides, and Toxic Substances. Available: http://www.epa.gov/opprd001/inserts/hydroxyd.htm [accessed 25 February 2015].

U.S. EPA. 2009. Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) Final Report. Available: http://www.epa.gov/scicopoly/oscpendo/pubs/edspooverview/finalrpt.htm [accessed 25 February 2015].

Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr, Lee DH, et al. 2012. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev 33:278–346.

Vandenberg LN, Welschon WV, van Saal FS, Toutain PL, Myers JP. 2014. Should oral gavage be abandoned in toxicity testing of endocrine disruptors? Environ Health 13:46; doi:10.1186/1476-069X-13-46.

Vo TT, Yoo YM, Choi KC, Jeung EB. 2010. Potential estrogenic effect(s) of parabens at the prepubertal stage of a postnatal female rat model. Reprod Toxicol 29:308–316.

Wolff MS, Engel SM, Berkowitz GS, Ye X, Silva MJ, Zhu C, et al. 2008. Prenatal phenol and phthalate exposures and birth outcomes. Environ Health Perspect 116:1092–1097; doi:10.1289/ehp.11007.

Wolff MS, Teitelbaum SL, McGovern K, Windham GC, Pinney SM, Galvez M, et al. 2014. Phthalate exposure and pubertal development in a longitudinal study of US girls. Hum Reprod 29:1558–1566.

Wolff MS, Teitelbaum SL, Pinney SM, Windham G, Liao L, Biro F, et al. 2010. Investigation of relationships between urinary biomarkers of phytosterogens, phthalates, and phenoils and pubertal stages in girls. Environ Health Perspect 118:1039–1046; doi:10.1289/ehp.0901890.

Ye X, Bishop AM, Reidy JA, Needham LL, Calafat AM. 2006. Parabens as urinary biomarkers of exposure in humans. Environ Health Perspect 114:1843–1846; doi:10.1289/ehp.94113.

Ye X, Kuklenyik Z, Needham LL, Calafat AM. 2005. Automated on-line column-switching HPLC-MS/MS method with peak focusing for the determination of nine environmental phenols in urine. Anal Chem 77:5407–5413.

Ye X, Tao LJ, Needham LL, Calafat AM. 2008. Automated on-line column-switching HPLC-MS/MS method for measuring environmental phenols and parabens in serum. Talanta 76:895–897.

Ye X, Zhou X, Hennings R, Kramer J, Calafat AM. 2013. Potential external contamination with bisphenol A and other ubiquitous organic environmental chemicals during biomonitoring analysis: an elusive laboratory challenge. Environ Health Perspect 121:283–286; doi:10.1289/ehp.1206003.